PTGX Stock Summary and Trading Ideas (Protagonist Therapeutics | NASDAQ:PTGX)

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Protagonist Therapeutics trades on the NASDAQ stock market under the symbol PTGX.

As of January 23, 2026, PTGX stock price declined to $83.10 with 555,143 million shares trading.

PTGX has a beta of -0.32, meaning it tends to be less sensitive to market movements. PTGX has a correlation of 0.01 to the broad based SPY ETF.

PTGX has a market cap of $5.17 billion. This is considered a Mid Cap stock.

Last quarter Protagonist Therapeutics reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .

In the last 3 years, PTGX traded as high as $96.54 and as low as $11.21.

The top ETF exchange traded funds that PTGX belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.

PTGX has outperformed the market in the last year with a price return of +119.8% while the SPY ETF gained +14.2%. PTGX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +12.3% and +3.6%, respectively, while the SPY returned +2.9% and -0.7%, respectively.

PTGX support price is $82.58 and resistance is $87.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTGX shares will trade within this expected range on the day.